Last Updated on February 13, 2025 by The Health Master
Export
The Directorate General of Foreign Trade (DGFT) has recently issued a very important amendment regarding the Standard Input Output Norms (SION) for the export of erythromycin stearate tablets.
This important amendment, mentioned in a public notice, aims to streamline trade operations for pharmaceutical exporters and to increase efficiency.
SION and its Importance
SION establishes standard norms and regulations for the input quantities required to manufacture a specific unit of output for export purposes.
These norms and regulations have been approved by the DGFT’s Board of Directors, and these are very important for obtaining advance licenses, which facilitate duty-free import of inputs for export production.
Key Highlights:
New Standards for Erythromycin Stearate Tablets:
The amendment introduces new input-output standards for erythromycin stearate 250 mg tablets.
Now onwards, each tablet requires 334 mg of erythromycin stearate as an import item.
Pro-rata Calculation:
Standards for other variants of the export product will be calculated pro-rata based on the revised norms for 250 mg tablets of erythromycin stearate.
Trade Facilitation:
According to Santosh Kumar Sarangi, Director General, Foregion Trade, this amendment will streamline all the procedures for export, improve the required compliance, and at the same time support the evolving needs of the pharmaceutical industry.
Benefits for Exporters:
The SION amendment is effective immediately, which will provide the exporters with clearer guidelines on input requirements and facilitate smoother trade operations.
Key Benefits for Exporters:
- More clear standards will minimize the administrative burden involved with obtaining advance licenses.
- The new streamlined processes will increase operational efficiency and also reduce time-to-market for export products.
- By providing smoother and easier trade operations, the said amendment will enhance the competitiveness of Indian pharmaceutical exports in the global market.
Where can we find the complete details of the SION amendment?
The complete details are available in the Public Notice issued by the DGFT and published in the Gazette of India Extraordinary.
How can we obtain further clarification on the amendment?
You can send your queries to the DGFT via email at dgft@nic.in.
Disclaimer: This article contains information obtained from the source mentioned below. Our team made changes in the format to rewrite and present the news or article in a unique format.
DGFT Introduces new norm for Clobetasol Propionate: A Boon for Pharma Exporters
Streamlining Pharma Exports: DGFT Introduces Electronic Submission system
Pharma Export: Implementation of Track and Trace system extended
Unlocking Opportunities: Pharmexcil Urges Exporters to Embrace DGFT Amnesty Scheme
CDSCO Approval: For Vedolizumab Biosimilar Clinical Trial
Campaign against counterfeit drugs from Feb 11: Rajasthan
Warning letter by USFDA: Let’s know all about it
Key Notes on Revised Schedule M: Investigational Pharmaceutical Products
No Ban on Methylcobalamin in India: Health Ministry
Drug recall: Saline and critical drugs recalled in West Bengal
Blood trafficking: Licences of 2 Blood Centres cancelled
Streamlining licensing of Class A and B Medical Device
FSSAI: Food Labelling and Display – Chapter-14
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
